Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas

COVID-19 monoclonal antibodies revolutionized the treatment for eligible patients who have tested positive for SARS CoV-2 infection in an ambulatory setting. In this short report, we describe our experience assisting in the distribution of monoclonal antibodies in Arkansas during the summer surge of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kothari, Atul, Woodland Borella, Elizabeth, Smith, Michelle R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754376/
https://www.ncbi.nlm.nih.gov/pubmed/35036464
http://dx.doi.org/10.1093/ofid/ofab602
_version_ 1784632261720670208
author Kothari, Atul
Woodland Borella, Elizabeth
Smith, Michelle R
author_facet Kothari, Atul
Woodland Borella, Elizabeth
Smith, Michelle R
author_sort Kothari, Atul
collection PubMed
description COVID-19 monoclonal antibodies revolutionized the treatment for eligible patients who have tested positive for SARS CoV-2 infection in an ambulatory setting. In this short report, we describe our experience assisting in the distribution of monoclonal antibodies in Arkansas during the summer surge of the delta variant.
format Online
Article
Text
id pubmed-8754376
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-87543762022-01-13 Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas Kothari, Atul Woodland Borella, Elizabeth Smith, Michelle R Open Forum Infect Dis Brief Report COVID-19 monoclonal antibodies revolutionized the treatment for eligible patients who have tested positive for SARS CoV-2 infection in an ambulatory setting. In this short report, we describe our experience assisting in the distribution of monoclonal antibodies in Arkansas during the summer surge of the delta variant. Oxford University Press 2022-01-10 /pmc/articles/PMC8754376/ /pubmed/35036464 http://dx.doi.org/10.1093/ofid/ofab602 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Kothari, Atul
Woodland Borella, Elizabeth
Smith, Michelle R
Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas
title Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas
title_full Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas
title_fullStr Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas
title_full_unstemmed Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas
title_short Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas
title_sort monoclonal antibody therapy for covid-19: a public health perspective from arkansas
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754376/
https://www.ncbi.nlm.nih.gov/pubmed/35036464
http://dx.doi.org/10.1093/ofid/ofab602
work_keys_str_mv AT kothariatul monoclonalantibodytherapyforcovid19apublichealthperspectivefromarkansas
AT woodlandborellaelizabeth monoclonalantibodytherapyforcovid19apublichealthperspectivefromarkansas
AT smithmicheller monoclonalantibodytherapyforcovid19apublichealthperspectivefromarkansas

Ejemplares similares